CG Oncology deck details cretostimogene bladder cancer data, FDA designations and manufacturing scale-up
The company's investor presentation covers its sole candidate, an unapproved oncolytic immunotherapy for NMIBC, citing no Grade 3 or higher treatment-related adverse events across three studies.
CG Oncology has published a corporate presentation centred on cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC). It is the company's only product candidate, and no regulator has approved it.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): CG Oncology, Inc. ↗
Article written by VigiEye from the official source (CG Oncology, Inc.). Claims are the company's own. AI-assisted; check the source before acting.